Advertisement

GI Dynamics Inc. (ASX: GID) announced approval from the U.S. Food and Drug Administration (FDA) to skip the pilot trial usually required for medical devices, allowing the company to move directly into a pivotal clinical trial of its lead product, a device for the treatment of obese patients who have uncontrolled type 2 diabetes.

Advertisement
Advertisement